Intermittent versus continuous androgen deprivation therapy

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 5, 2014, Pages 727-733

  Higano, Celestia S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; CANADA; CONTINUOUS ANDROGEN DEPRIVATION THERAPY; DECISION MAKING; GLEASON SCORE; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; INTERMITTENT ANDROGEN DEPRIVATION THERAPY; NATIONAL HEALTH ORGANIZATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATECTOMY; QUALITY OF LIFE; REVIEW; ADENOCARCINOMA; ANIMAL; DRUG ADMINISTRATION; MALE; PROSTATIC NEOPLASMS;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84900457585     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0074     Document Type: Review

References (17)

1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9-12.
2. Chi KN, Nguyen PL, Higano CS. Androgen deprivation for prostate cancer. Available at: http://meetinglibrary.asco.org/content/24-132. Accessed April 2, 2014.
3. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58:2546-2550. (Pubitemid 17191621)
4. Akakura K, Bruchovsky N, Goldenberg SL, et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993;71:2782-2790. (Pubitemid 23120055)
5. Akakura K, Bruchovsky N, Rennie PS, et al. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma. J Steroid Biochem Mol Biol 1996;59:501-511. (Pubitemid 27037917)
6. Goldenberg SL, Bruchovsky N, Gleave ME, et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995;45:839-844.
7. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996;48:800-804. (Pubitemid 26409365)
8. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49-59.
9. Crook J. The role of intermittent androgen suppression in biochemically recurrent or newly diagnosed metastatic prostate cancer. Curr Opin Support Palliat Care 2013;7:258-264.
10. Wright JL, Higano CS, Lin DW. Intermittent androgen deprivation: clinical experience and practical applications. Urol Clin North Am 2006;33:167-179, vi.
11. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368:1314-1325.
12. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367:895-903.
13. Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012;109:32-39.
14. Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol, in press.
15. Higano C, Shields A, Wood N, et al. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004;64:1182-1186. (Pubitemid 39647063)
16. Hussain M, Tangen CM, Higano C, et al. Absolute prostatespecific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 2006;24:3984-3990. (Pubitemid 46630748)
17. NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy. National Institutes of Health Web site. Available at: http://www.nih.gov/news/health/ dec2013/nci-05.htm. Accessed April 3, 2014.